| ID | Sequence | Length | GC content |
|---|---|---|---|
| GACUACGGCGGGCGCUGUGGGAGUGGAGAAGCUGCAAGUGCUGAGGCGC… | 3124 nt | 0.3796 | |
| GACUACGGCGGGCGCUGUGGGAGUGGAGAAGCUGCAAGUGCUGAGGCGC… | 3304 nt | 0.3798 | |
| GACUACGGCGGGCGCUGUGGGAGUGGAGAAGCUGCAAGUGCUGAGGCGC… | 3560 nt | 0.3986 | |
| GACUACGGCGGGCGCUGUGGGAGUGGAGAAGCUGCAAGUGCUGAGGCGC… | 3354 nt | 0.3825 | |
| GACUACGGCGGGCGCUGUGGGAGUGGAGAAGCUGCAAGUGCUGAGGCGC… | 3532 nt | 0.3998 | |
| GACUACGGCGGGCGCUGUGGGAGUGGAGAAGCUGCAAGUGCUGAGGCGC… | 3276 nt | 0.3810 | |
| GACUACGGCGGGCGCUGUGGGAGUGGAGAAGCUGCAAGUGCUGAGGCGC… | 462 nt | 0.5173 | |
| GACUACGGCGGGCGCUGUGGGAGUGGAGAAGCUGCAAGUGCUGAGGCGC… | 3104 nt | 0.3782 |
Predicted to enable microtubule binding activity. Predicted to be active in microtubule cytoskeleton; nucleus; and sperm flagellum. [provided by Alliance of Genome Resources, Apr 2025]
A study in human cardiac stromal cells from arrhythmogenic cardiomyopathy (ACM) patients identified SAXO2 as a significantly up-regulated gene in ACM samples compared to healthy controls [Rainer et al. DOI:10.1186/s12864-018-4876-6]. This differential expression was confirmed by RT-qPCR validation in an extended sample set, establishing it as part of the ACM-specific transcriptomic signature.